RxDoctor Payments Data

Cody Becksvoort, DO

Family Medicine · Sumter, SCNPI 1831572619

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 41 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • Exact Sciences$150
  • Astellas Pharma US Inc$100
  • Axsome Therapeutics, Inc.$75
  • Novo Nordisk$68
  • Lilly USA, LLC$65
  • plus $256 from 10 others

What the payments were for

  • Food & beverage$93390%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,033 in reported general payments places this provider in the 60th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$308,176
Medicare patients
328
Services billed
12,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide129$172,835
TrulicityDulaglutide107$129,740
OzempicSemaglutide49$64,405
Dupixent PenDupilumab12$43,318
JardianceEmpagliflozin43$37,393
VraylarCariprazine Hcl26$36,227
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$35,361
FarxigaDapagliflozin Propanediol25$23,340
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$20,129
EliquisApixaban24$18,347
EntrestoSacubitril/Valsartan17$16,831
Janumet XrSitagliptin Phos/Metformin Hcl13$14,272
XareltoRivaroxaban16$13,912
LinzessLinaclotide22$12,721
MyrbetriqMirabegron18$11,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$65$302,575236 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$16$68,01385 claims
Novo NordiskOzempic$68$64,40549 claims
AbbVieVraylar, Linzess$319$48,94848 claims
PfizerEliquis, Premarin$16$26,79147 claims
AstraZenecaFarxiga$35$23,34025 claims
NovartisEntresto$34$16,83117 claims
Astellas Pharma US IncMyrbetriq$100$11,49818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →